Impact News +++ Nouveau Monde Graphite plans to raise capital via stock (SeekingAlpha) +++ NOUVEAU MONDE Aktie -4,89%

CARDIOL Aktie

>CARDIOL Aktienkurs

0.853 EUR (Tradegate)

Ask: 0.869 EUR / 1151 Stück

Bid: 0.836 EUR / 1198 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CARDIOL Aktie über LYNX handeln

Intraday

1 Jahr

>CARDIOL Performance

1 Woche: -5,0%

1 Monat: +0,6%

3 Monate: -7,8%

6 Monate: -28,2%

1 Jahr: -34,1%

laufendes Jahr: -30,7%

>CARDIOL Aktie

Name:

CARDIOL THERAPEUTICS CL.A

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA14161Y2006 / A2PA9E

Symbol/ Ticker:

CT9 (Frankfurt)

Kürzel:

FRA:CT9, ETR:CT9, CT9:GR

Index:

Webseite:

https://www.cardiolrx.com..

Profil:

Cardiol Therapeutics Inc. is a clinical-stage biot..
>Volltext..

Marktkapitalisierung:

87.96 Mio. EUR

Unternehmenswert:

80.92 Mio. EUR

Umsatz:

EBITDA:

-22.12 Mio. EUR

Nettogewinn:

-21.29 Mio. EUR

Gewinn je Aktie:

-0.26 EUR

Schulden:

0.08 Mio. EUR

Liquide Mittel:

7.11 Mio. EUR

Operativer Cashflow:

-14.82 Mio. EUR

Bargeldquote:

3.53

Umsatzwachstum:

Gewinnwachstum:

11.27%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CARDIOL

Letzte Datenerhebung:

18.12.25

>CARDIOL Kennzahlen

Aktien/ Unternehmen:

Aktien: 100 Mio. St.

Frei handelbar: 95.72%

Leerverk. Aktien: -

Rückkaufquote: -13.04%

Mitarbeiter: 22

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 570.29%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 13.6

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -228.34%

Eigenkaprendite: -347.98%

>CARDIOL Peer Group

Es sind 182 Aktien bekannt.

>CARDIOL Chart & Kurs - Tradegate

>CARDIOL News

01.12.25 - 13:42	Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions (Newsfile)
	Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients w......

13.11.25 - 13:54	Cardiol Therapeutics Inc.: Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 (Newsfile)
	Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual p......

05.11.25 - 14:01	Cardiol Therapeutics Inc.: Cardiol Therapeutics′ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases (Newsfile)
	The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial follo......

21.10.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 (Newsfile)
	MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARC......

20.10.25 - 14:25	XFRA: CT9: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 AB/FROM ONWARDS 20.10.2025 14:14 CET...

20.10.25 - 08:42	XFRA: CT9: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 BAW/UFN...

20.10.25 - 08:36	XFRA: INSTRUMENT_SUSPENSION - CA14161Y2006 (XETRA)
	Instrument ID [6186088] (CT9 - CA14161Y2006) suspended...

17.10.25 - 22:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 (Newsfile)
	MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARC......

15.10.25 - 13:45	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
	Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery....

11.08.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity′s 45th Annual Growth Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developi......

06.08.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis (Newsfile)
	Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with i......

22.07.25 - 21:03	Cardiol rises on database lockup for acute myocarditis therapy trial (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.07.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx in Acute Myocarditis (Newsfile)
	ARCHER is designed to assess the impact of CardiolRx on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis i......

29.05.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ......

27.05.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ......

29.04.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developin......

22.04.25 - 15:15	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
	Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors....

16.04.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis (Newsfile)
	Designed to assess the impact of CardiolRx on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-o......

01.04.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Year-End 2024 Update on Operations (Newsfile)
	Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis; results support advancing to th......

03.03.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer lesen kann, der ist niemals einsam. - Prof. Dr. Walter Jens

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram